Clinical Trials Directory

Trials / Completed

CompletedNCT03548597

Evaluation of the Diagnostic of Hepatic Fibrosis With the in Severe Obese Patients Candidates to Bariatric Surgery

Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery

Status
Completed
Phase
Study type
Observational
Enrollment
132 (actual)
Sponsor
European Georges Pompidou Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Background: The XL probe of FibroScan was recently developed to realize liver stiffness measurements (LSM) in overweight patients. Severe obese patients have a high prevalence of liver injuries and could benefit of liver evaluation prior to bariatric surgery. Objectives: Assess the FibroScan applicability, reliability and diagnostic performances in severe obese patients' candidates for bariatric surgery.

Conditions

Interventions

TypeNameDescription
DEVICEEvaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric SurgeryEvaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery

Timeline

Start date
2012-04-04
Primary completion
2015-01-12
Completion
2016-12-06
First posted
2018-06-07
Last updated
2018-06-07

Source: ClinicalTrials.gov record NCT03548597. Inclusion in this directory is not an endorsement.